Company Focus

Otsuka

Latest Otsuka News

FDA accepts Taiho’s sNDA for Inqovi
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted the supplemental new drug application (sNDA) for Inqovi (decitabine and cedazuridine) plus venetoclax as a treatment for adults with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive induction chemotherapy.   10 July 2025


Insights

Company Spotlight

Latest News & Features of interest to Otsuka

Latest Relevant Ones To Watch News


More in M&A >


Relevant Ones to Watch Companies

Reset all filters
Refine Search